Applied Therapeutics (APLT) director stock and options cashed out
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Applied Therapeutics, Inc. completed a merger in which each common share was converted into cash and a contingent value right. Under the Merger Agreement with Cycle Group Holdings Limited and AT2B, INC., each outstanding share became entitled to receive $0.088 in cash per share plus one non-tradeable contingent value right.
Director Skyler Jay S tendered all common shares for this merger consideration and no longer holds Applied Therapeutics stock. In addition, several stock options with exercise prices at or above the cash amount were fully vested and then cancelled at the merger’s effective time without any payment.
Positive
- None.
Negative
- None.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
SKYLER JAY S
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 20,460 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 10,230 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 16,500 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 16,500 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 200,000 | $0.00 | -- |
| Disposition | Common Stock | 22,500 | $0.00 | -- |
| U | Common Stock | 42,500 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct);
Common Stock — 42,500 shares (Direct)
Footnotes (1)
- Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration. Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration. Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.
FAQ
What insider transaction did Applied Therapeutics (APLT) director Skyler Jay S report?
Director Skyler Jay S reported tendering all Applied Therapeutics common shares in connection with a completed merger. The shares were converted into the right to receive $0.088 per share in cash plus one non-tradeable contingent value right, leaving no remaining common stock ownership.
What merger affected Applied Therapeutics (APLT) director holdings in this Form 4?
A merger under a December 11, 2025 Merger Agreement among Applied Therapeutics, Cycle Group Holdings Limited and AT2B, INC. affected the director’s holdings. The merger became effective January 28, 2026, after a tender offer, with Applied Therapeutics surviving as the post-merger entity.
How were Applied Therapeutics (APLT) restricted stock units treated in the merger?
At the effective time of the merger, each outstanding restricted stock unit, whether vested or unvested, was deemed to have vested, then cancelled and automatically converted into the right to receive the same merger consideration as common shares: $0.088 in cash per share plus one non-tradeable contingent value right.
What happened to Applied Therapeutics (APLT) stock options in this Form 4?
At the merger effective time, each stock option with a per-share exercise price equal to or above the $0.088 cash amount was fully vested and then cancelled for no consideration. These out-of-the-money options, including those reported by the director, ceased to exist after the merger closed.